This downramper (realist) has been busy on the EOF IPO that floated up 61% and closed 70% up. Sorry, busy following a company and ceo with a little more walk than talk
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%